A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...
MedPage Today on MSN
Paradigm Shift for Evaluating, Treating Biochemical Recurrence in Prostate Cancer
When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...
UCLA researchers found that routine PSMA PET/CT scans could help doctors select treatment approaches for the best long-term outcomes in patients with recurring prostate cancer after surgical removal ...
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.
Please provide your email address to receive an email when new articles are posted on . Researchers at The Ohio State University have harnessed artificial intelligence machine learning processes to ...
Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...
In metastatic prostate cancer, AI-facilitated quantification of metastatic burden, accurate identification of castration resistance, and prediction of treatment sensitivity and resistance are active ...
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for ...
When prostate cancer has spread beyond the prostate to nearby lymph nodes and other areas of the body and treatments can no longer slow or stop its growth, you are not alone. Many patients, despite ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results